“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...
The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...
In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.
Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...
In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.
Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
Shares of Moderna Inc. fell over 8% on Wednesday afternoon, paring some of the gains from Tuesday, the stock’s best trading ...